Genelabs Announces Presentation Of Data On Non-Nucleoside HCV Polymerase Inhibitor At International Symposium On Hepatitis C Virus And Related Viruses

Main Category: Liver Disease / Hepatitis
Article Date: 10 Oct 2008 - 6:00 PDT

email to a friend   printer friendly   opinions  

Genelabs Technologies, Inc. (Nasdaq:GNLB) announced that three presentations were made at the 15th International Symposium on Hepatitis C Virus and Related Viruses, each on a non-nucleoside hepatitis C virus (HCV) polymerase inhibitor discovered by Genelabs.

The presentations focused on the discovery, in vitro antiviral activity, resistance profile, pharmacokinetics and mechanism of action of GL60667 (NVP-LDI133), a potent non-nucleoside inhibitor of the HCV NS5B polymerase. The presentations contain studies performed by both Genelabs and Novartis scientists in connection with the license and research collaboration commenced in June of 2006 between the companies, covering Genelabs non-nucleoside HCV polymerase inhibitors. GL60667 is one of a number of non-nucleoside HCV polymerase inhibitors discovered by Genelabs.

"The presentations made describe the discovery of new site 1 non-nucleoside polymerase inhibitors with potent anti-HCV activity" said Ronald C. Griffith, Ph.D., Genelabs' Chief Scientific Officer. "Other compounds from this class continue to advance forward in preclinical studies and we are very pleased with the progress made to date."

About Genelabs Technologies

Genelabs is a biopharmaceutical company focused on the discovery and development of novel compounds for infectious diseases. In addition to a late-stage vaccine candidate for hepatitis E virus partnered with GlaxoSmithKline, the company is advancing both partnered and proprietary compounds designed to selectively inhibit replication of the hepatitis C virus. For more information, please visit http://www.genelabs.com.

Note On Forward Looking Statements And Risks

This press release contains forward-looking statements regarding the quality and continued development of a therapeutic compound for the treatment of HCV infection. These forward-looking statements are based on Genelabs' current expectations and are subject to uncertainties and risks that could cause actual results to differ materially from the statements made, including, without limitation, uncertainties and risks associated with the preclinical development of therapeutic compounds and the continued commitment of Genelabs' collaborative partner. Please see the information appearing in the company's filings with the Securities and Exchange +Commission, including the most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, under the captions "Risk Factors," "Business Risks" and "Forward-Looking Statements" for more discussion regarding these uncertainties and risks and other risks that may cause actual results to differ from those included in the forward-looking statements. Genelabs does not undertake any obligation to update these forward-looking statements or risks to reflect events or circumstances after the date of this release.

Genelabs Technologies

• Additional
• References
• Citations